Please assess the completion status of the following clinical trial:

Trial Title: Marinol in Trichotillomania or Obsessive Compulsive Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-65 years~2. Obsessive-compulsive disorder (OCD), Trichotillomania (TTM), or Pathological Skin Picking (PSP) as the primary psychiatric diagnosis~3. (If OCD) - Subject reports ≥two failed treatments using selective serotonin reuptake inhibitors (SSRIs) for their OCD~4. Women's participation required negative results on a beta-human chorionic gonadotropin pregnancy test and stable use of a medically accepted form of contraception.~5. Signed informed consent before entry into the study.~Exclusion Criteria:~1. Unstable medical illness or clinically significant abnormalities on laboratory tests or physical examination at screening visit~2. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential~3. A need for medication other than dronabinol with possible psychotropic effects~4. History of hypersensitivity to any cannabinoid or sesame oil~5. Lifetime history of bipolar disorder type I or II, dementia, or schizophrenia as determined by the Structured Clinical Interview for DSM-IV~6. Current (past 12-months) DSM-IV substance abuse or dependence~7. Positive urine drug screen at screening~8. Initiation of cognitive behavior therapy within 3 months prior to study baseline~9. Baseline score of ≥ 17 on the Hamilton Depression Rating Scale (17-item HDRS~10. Suicidality based on clinical interview~11. History of head injury or neurological disorder (such as seizures)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dronabinol (Type: EXPERIMENTAL): Dronabinol (Marinol) - 2.5mg-15mg by mouth once a day for twelve-weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).